CAPR

Business Context and Reporting Period

Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Capricor is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics, primarily for Duchenne muscular dystrophy (DMD). The company's lead product candidate, Deramiocel, is currently under FDA review with a PDUFA target action date of August 22, 2026. The company has no approved products and generates no product revenue.

Key Financial Metrics

Note: The company reported no revenue for the periods presented. Operating expenses consist primarily of Research and Development (R&D) and General and Administrative (G&A) costs.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the six months ended June 30, 2026, increased by approximately $24.4 million (48%) compared to the same period in 2025, driven by higher operating expenses.
• R&D Expenses: Increased by $15.3 million (37%) year-over-year for the six-month period. This was primarily due to expanded manufacturing production for Deramiocel, commercial preparation costs, and increased headcount.
• G&A Expenses: Increased by $11.7 million (100%) year-over-year for the six-month period. The surge was largely attributable to a $6.6 million increase in professional services (legal and consulting) related to regulatory and pre-commercial initiatives, as well as facility expansion costs.
• Liquidity Position: Total cash, cash equivalents, and marketable securities decreased from $318.1 million at December 31, 2025, to $237.9 million at June 30, 2026. This $80.2 million decrease reflects operating cash burn and net purchases of marketable securities.
• Lease Liabilities: Significant increase in lease liabilities due to the commencement of a new long-term lease for expanded corporate headquarters and manufacturing facilities in San Diego (ARE Lease), recognized as a right-of-use asset of approximately $76.3 million.

Guidance, Outlook, Risks, and Contingencies

Regulatory Status and Outlook

• Deramiocel BLA: The FDA Advisory Committee voted 3-9 against the effectiveness of Deramiocel for the treatment of cardiomyopathy in DMD patients on July 29, 2026. The company plans to submit an amended BLA focusing on the primary endpoint (upper limb function) and 24-month open-label extension data. The FDA has agreed to review the amendment, which will extend the PDUFA date.
• Statistical Update: A revised statistical model for the HOPE-3 trial showed a p-value of 0.09 for the LVEF secondary endpoint (previously 0.04), though the primary endpoint remained statistically significant (p=0.029).

Legal and Litigation Risks

• Nippon Shinyaku (NS) Dispute: Capricor filed a complaint alleging NS failed to prepare for the commercial launch of Deramiocel in the U.S. and breached the distribution agreement. Capricor seeks rescission of the agreement. The company withdrew a preliminary injunction motion to pursue arbitration following the FDA decision, with arbitration expected to begin in fall 2026.
• Patent Infringement: Mesoblast International Sàrl filed a patent infringement lawsuit in July 2026 alleging unauthorized manufacture and sale of Deramiocel.
• Securities Litigation: Multiple securities class actions and derivative suits have been filed against the company and its directors in 2025 and 2026 alleging violations of securities laws and breaches of fiduciary duty.

Liquidity and Capital Resources

Management believes current cash and marketable securities ($237.9 million) are sufficient to fund operations for at least the next 12 months. However, the company expects to incur significant losses and may require additional financing to support commercialization efforts if Deramiocel is approved.

Key Facts for Investor Verification

• Regulatory Hurdle: Verify the impact of the negative FDA Advisory Committee vote on the likelihood and timing of Deramiocel approval, specifically regarding the amended BLA strategy.
• Distribution Uncertainty: Assess the outcome of the arbitration with Nippon Shinyaku, as the company's ability to commercialize Deramiocel in the U.S. and generate revenue depends on resolving this dispute.
• Cash Burn Rate: Monitor the quarterly cash burn rate (approx. $37 million for the six-month period) against the current cash balance of $237.9 million to determine runway.
• Lease Obligations: Review the terms of the new San Diego lease (ARE Lease), which includes a significant tenant improvement allowance and rent abatement, but creates substantial long-term lease liabilities.
• Legal Exposure: Track the progress of the Mesoblast patent infringement suit and ongoing securities litigation, which could result in significant costs or operational restrictions.